American Stem Cells: USRM to Focus on Animal Health and Lead Innovation in Pet Care
SUNRISE, FL – October 18, 2021 – US Stem Cell, Inc. (OTC: USRM), a leader in the development of stem cell therapies and novel proprietary regenerative medicine solutions, will take action to revive its veterinary division to tackle innovation in animal health.
US Stem Cell’s long-standing animal division, Vetbiologics, has been providing the veterinary field with comprehensive regenerative medicine solutions for years – from training to products and services. Vetbiologics is now aiming to grow further by entering directly into the consumer-driven pet care industry.
The turnover of the US pet market has grown every year for the past decade from $ 50.96 billion in 2011 to about $ 99.1 billion Last year. The companion animal industry has experienced extraordinary growth during the COVID-19 pandemic; an impressive 12% of adults with children have adopted pets because of and during the pandemic, effectively leaving animal shelters empty for the first time in U.S. history. These middle-aged pets are aging now, with many with specialized needs – paired with richer pet parents with significantly larger budgets to care for their aging pets. Among these pet owners, 21% spent more time and money with their pets during the pandemic and the trends are on the rise.
The Animal Health division will focus on these new demands of aging pets, with particular emphasis on pet care, pain, welfare and geriatric care.
âThe company’s expansion and growth will directly target consumers as they adjust to pet ownership during and after the pandemic,â said Mike Tomas, President and CEO. Adding “taking care of their newly adopted middle aged or senior animals as a top priority for the welfare of their pets, we will provide solutions for pet parents.”
Considering the expected market growth and trends in the companion animal industry, through the Vetbiologics division, the Company aims to establish strategic partnerships and develop leading products and services in accordance with the successes expected in the field. These offerings will be in addition to Vetbiologics’ existing menu of scientific regenerative treatments and veterinarian-specific options.
American Stem Cells, Inc. is an emerging leader in the regenerative medicine / cell therapy industry specializing in the training and certification of physicians and stem cell products in human and veterinary stem cell processes. To management’s knowledge, USRM has performed more clinical treatments than any other stem cell company in the world over the past 20 years and has certified over 700 physicians and veterinarians in autologous stem cell therapy worldwide. The company will refocus on its animal health division as it assesses future opportunities for its human division and its subsidiary.
Forward-Looking Statements: Except for historical information contained in this document, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend to” “,” Could “,” could “,” estimate “or” continue “, or other negative variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to differ materially from future results, performance or achievements expressed or implied by forward-looking statements. and represent beliefs and assumptions only as of the date hereof. Unless required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The business of the Company and the risks and uncertainties of the business are described in its documents filed with the Securities and Exchange Commission which can be viewed at sec.gov.
# # #